Navigation Links
Upcoming Webinar to Inform Public About Access to Investigational Drugs
Date:2/19/2010

First in the 'FDA Basics' Series of Online Sessions for the Public

SILVER SPRING, Md., Feb. 19 /PRNewswire-USNewswire/ -- Do you have questions about the use of investigational drugs for treatment purposes? Here is your opportunity to ask experts from the Food and Drug Administration (FDA) about this important topic, or to just listen in to learn more about investigational drugs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

When: Tuesday, Feb. 23, 2010, at 3 p.m. ET

Where: https://webmeeting.nih.gov/expandedaccess/

Host: FDA's Office of Special Health Issues (OSHI), 301-827-4460, OSHI@oc.fda.gov

Speakers:

Richard Klein, HIV/AIDS program director, OSHI

Theresa Toigo, R.Ph., M.B.A., director, OSHI

Also known as experimental drugs, investigational drugs are new drugs that are in the process of being tested for safety and effectiveness. They either have not yet been approved by FDA, or are approved drugs that have not yet been approved for a new use.

Investigational drugs may sometimes be used outside of clinical trials to treat a patient with a serious or immediately life-threatening disease or condition who has no other comparable or satisfactory treatment options. This use is called expanded access, or "compassionate use."

During this webinar, FDA experts will present information on

  • factors to consider in deciding whether to seek access to an investigational drug
  • ways to access investigational drugs
  • how the agency protects patients using investigational drugs

The presentation will run 30 minutes and will include an opportunity to ask questions.

To join the webinar:

  1. Click https://webmeeting.nih.gov/expandedaccess/ (or cut and paste it into your Internet browser).
  2. Click "Enter as a Guest," fill in your name, then click "Enter Room."
  3. Once you enter the meeting room, a popup will appear inviting you to join the teleconference. Type your own telephone number, then click "Call my phone" or "Call me." Answer your phone when it rings and follow the voice prompts to join the teleconference.

NOTE: If your phone number includes an extension, or if you will attend the teleconference only (not the online visual portion), please use the manual dial-in number: 1-866-628-8620 and passcode: 340910

To verify your ability to access the webinar (recommended for first-time Connect users):

  1. Click http://nihbreeze.cit.nih.gov/common/help/en/support/meeting_test.htm (or cut and paste it into your Internet browser).
  2. If any failures are indicated, click "Send Results" to submit your test results to Tech Support. Then e-mail webmeeting@mail.nih.gov and indicate that you would like assistance with troubleshooting your computer.

This webinar is the first in a series of monthly online sessions hosted by different FDA centers and offices. The webinar series is part of FDA Basics, a Web-based resource aimed at helping the public better understand what the agency does.

Sign up for e-mail notices of new FDA Consumer Updates at: https://service.govdelivery.com/service/subscribe.html?code=USFDA_9.


View the FDA Consumer Update RSS feed at: http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Consumers/rss.xml

FDA Consumer Updates may be posted and published elsewhere without permission. Please credit "FDA Consumer Health Information (www.fda.gov/consumer)" as the source. FDA values feedback on its consumer health information. Send questions, comments, or story ideas to: consumerinfo@fda.hhs.gov.

SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov/AboutFDA/Basics

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
3. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
4. IDM Pharma Announces Upcoming Clinical Data Presentations
5. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
6. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
7. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
8. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
9. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
10. Genmab Announces Upcoming Ofatumumab Studies
11. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
Breaking Medicine News(10 mins):